Johnson & Johnson study shows XARELTO® Plus Aspirin Significantly Reduced Total Ischemic Events
Phase 3 VOYAGER PAD is the first investigational study in 20 years to highlight the benefit ...
Read morePhase 3 VOYAGER PAD is the first investigational study in 20 years to highlight the benefit ...
Read moreJohnson & Johnson announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.